{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:42:38Z","timestamp":1791308558281,"version":"4.3.1"},"reference-count":254,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004367","name":"Taiwan Association for the Study of the Liver","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013460","name":"Taiwan Liver Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013460","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jfma.2020.04.002","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T16:49:33Z","timestamp":1588006173000},"page":"1135-1157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations"],"prefix":"10.1016","volume":"119","author":[{"given":"Ming-Lung","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2020.04.002_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.ajkd.2010.01.015","article-title":"Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study","volume":"56","author":"Lee","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1440-1746.2010.06488.x","article-title":"Treatment of hepatitis C virus infection in patients with end-stage renal disease","volume":"26","author":"Liu","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178883","article-title":"Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients","volume":"12","author":"Jang","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.jfma.2020.04.002_bib4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s12072-009-9147-9","article-title":"Dual chronic hepatitis B virus and hepatitis C virus infection","volume":"3","author":"Liu","year":"2009","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2020.04.002_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094791","article-title":"Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection","volume":"9","author":"Hsieh","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.jfma.2020.04.002_bib6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jfma.2011.06.022","article-title":"Seroprevalence of hepatitis virus infection in men who have sex with men aged 18-40 years in Taiwan","volume":"111","author":"Tseng","year":"2012","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2020.04.002_bib7","article-title":"Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan","volume":"13","author":"Li","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.jfma.2020.04.002_bib8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs","volume":"71","author":"Llaneras","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib9","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jfma.2020.04.003","article-title":"2020 Taiwan consensus statement on the management of hepatitis C: Part (I) general population","volume":"119","author":"Yu","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2020.04.002_bib10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41575-018-0026-5","article-title":"Management of acute HCV infection in the era of direct-acting antiviral therapy","volume":"15","author":"Martinello","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrgastro.2011.32","article-title":"Treatment of acute HCV infection","volume":"8","author":"Grebely","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(08)61116-2","article-title":"Acute hepatitis C","volume":"372","author":"Maheshwari","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2020.04.002_bib13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jhep.2013.09.023","article-title":"High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients","volume":"60","author":"Yu","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib14","doi-asserted-by":"crossref","first-page":"17030","DOI":"10.1038\/srep17030","article-title":"Polymorphisms near the IFNL3 gene associated with HCV RNA spontaneous clearance and hepatocellular carcinoma risk","volume":"5","author":"Lee","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2020.04.002_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0016-5085(03)00668-1","article-title":"Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance","volume":"125","author":"Gerlach","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2020.04.002_bib16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1473-3099(13)70059-8","article-title":"Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial","volume":"13","author":"Deterding","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/hep.29611","article-title":"Should we treat acute hepatitis C? A decision and cost-effectiveness analysis","volume":"67","author":"Bethea","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210179","article-title":"Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men","volume":"14","author":"Popping","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.jfma.2020.04.002_bib19","first-page":"S806","article-title":"Sofosbuvir and ledipasvir versus sofosbuvir and simeprevir combination therapy in the management of acute hepatitis C: a randomized open label prospective clinical pilot study. Slam C study","volume":"64","author":"Basu","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1473-3099(16)30408-X","article-title":"Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study","volume":"17","author":"Deterding","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S2468-1253(17)30003-1","article-title":"Ledipasvir\u2013sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial","volume":"2","author":"Rockstroh","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib22","doi-asserted-by":"crossref","first-page":"ofy238","DOI":"10.1093\/ofid\/ofy238","article-title":"New York Acute Hepatitis C Surveillance Network. Ledipasvir and sofosbuvir in the treatment of early hepatitis C virus infection in HIV-infected men","volume":"5","author":"Palaniswami","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib23","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/cid\/ciy913","article-title":"Ledipasvir\/sofosbuvir for 8 weeks to treat acute hepatitis C virus infections in men with human immunodeficiency virus infections: sofosbuvir-containing regimens without interferon for treatment of acute HCV in HIV-1 infected individuals","volume":"69","author":"Naggie","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib24","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/jvh.12917","article-title":"Shortened therapy of eight weeks with paritaprevir\/ritonavir\/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection","volume":"25","author":"Martinello","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2020.04.002_bib25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S2468-1253(18)30414-X","article-title":"Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial","volume":"4","author":"Boerekamps","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/S0618-8278(19)30432-3","article-title":"Short duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with recent HCV infection","author":"Martinello","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1080\/15284336.2017.1280594","article-title":"Sofosbuvir in the treatment of early HCV infection in HIV-infected men","volume":"18","author":"El Sayed","year":"2017","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.jfma.2020.04.002_bib28","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/hep.28844","article-title":"Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: the DARE-C II study","volume":"64","author":"Martinello","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib29","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/cid\/cix025","article-title":"Sofosbuvir plus ribavirin without interferon for treatment of acute hepatitis C virus infection in HIV-1-infected individuals: swift-C","volume":"64","author":"Naggie","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib30","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(19)32320-7","article-title":"Hepatitis C","volume":"394","author":"Spearman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2020.04.002_bib31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1055\/s-0039-1687823","article-title":"Retreatment of hepatitis C virus-infected patients with direct-acting antiviral failures","volume":"39","author":"Pawlotsky","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185728","article-title":"Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: interim evaluations from the PITER network","volume":"12","author":"Kondili","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.jfma.2020.04.002_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222605","article-title":"Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: a retrospective study with prospectively collected data","volume":"14","author":"Yen","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.jfma.2020.04.002_bib34","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2019.07.020","article-title":"Real-life effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in hepatitis C patients with previous DAA failure","volume":"71","author":"Degasperi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2020.04.002_bib36","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/jvh.13115","article-title":"Real-world effectiveness of sofosbuvir\/velpatasvir\/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients","volume":"26","author":"Belperio","year":"2019","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2020.04.002_bib37","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib38","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jhep.2019.05.021","article-title":"A pilot study of safety and efficacy of HCV retreatment with sofosbuvir\/velpatasvir\/voxilaprevir in patients with or without HIV (RESOLVE STUDY)","volume":"71","author":"Wilson","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib39","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.14309\/ajg.0000000000000248","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir for previous treatment failures with glecaprevir\/pibrentasvir in chronic hepatitis C infection","volume":"114","author":"Pearlman","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jfma.2020.04.002_bib40","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/hep.29256","article-title":"Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen","volume":"66","author":"Gane","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib41","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s12072-018-9878-6","article-title":"Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals","volume":"12","author":"Izumi","year":"2018","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2020.04.002_bib42","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.29671","article-title":"Glecaprevir\/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure","volume":"67","author":"Poordad","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib43","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1053\/j.gastro.2019.08.008","article-title":"Efficacy of glecaprevir and pibrentasvir in patients with genotype 1 hepatitis C virus infection with treatment failure after NS5A inhibitor plus sofosbuvir therapy","volume":"157","author":"Lok","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2020.04.002_bib44","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s00535-017-1396-0","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection","volume":"53","author":"Kumada","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2020.04.002_bib45","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jhep.2019.01.031","article-title":"Retreatment of patients who failed glecaprevir\/pibrentasvir treatment for hepatitis C virus infection","volume":"70","author":"Wyles","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib46","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.28877","article-title":"Short-duration treatment with elbasvir\/grazoprevir and sofosbuvir for hepatitis C: a randomized trial","volume":"65","author":"Lawitz","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib47","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/cid\/cix916","article-title":"Retreatment with sofosbuvir plus grazoprevir\/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed an NS5A- or NS3-containing regimen: the ANRS HC34 REVENGE Study","volume":"66","author":"de L\u00e9dinghen","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib48","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/hep.29192","article-title":"Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study","volume":"66","author":"Lai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib49","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jvh.12148","article-title":"Meta-analysis of observational studies: hepatitis C and survival after renal transplant","volume":"21","author":"Fabrizi","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2020.04.002_bib50","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2215\/CJN.01530218","article-title":"Kidney function decline in patients with CKD and untreated hepatitis C infection","volume":"13","author":"Tartof","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2020.04.002_bib51","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","article-title":"Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection","volume":"64","author":"Hsu","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2020.04.002_bib52","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jhep.2019.11.014","article-title":"Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals","volume":"72","author":"Liu","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01990-17","article-title":"Effects of renal impairment and hemodialysis on the pharmacokinetics and safety of the glecaprevir and pibrentasvir combination in hepatitis C virus-negative subjects","volume":"62","author":"Kosloski","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jfma.2020.04.002_bib54","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00228-018-2585-3","article-title":"Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment","volume":"75","author":"Caro","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jfma.2020.04.002_bib55","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib56","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2020.04.002_bib57","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/jgh.14447","article-title":"Efficacy and safety of elbasvir\/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: a post hoc analysis of a multicenter study","volume":"34","author":"Atsukawa","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib58","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/j.gastro.2019.05.007","article-title":"Amino acid substitutions in genotype 3a hepatitis C virus polymerase protein affect responses to sofosbuvir","volume":"157","author":"Wing","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2020.04.002_bib59","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2020.04.002_bib60","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12\u202fweeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","volume":"71","author":"Borgia","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib61","first-page":"A99","article-title":"Safety and efficacy of treatment with once-daily LEDIPASVIR\/SOFOSBUVIR (90\/400 MG) for 12 weeks in genotype 1 hcv-infected patients with severe renal impairment","volume":"67","author":"Lawitz","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2020.04.002_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(19)40381-8","article-title":"Ledipasvir\/sofosbuvir for 8, 12, or 24 weeks is safe and effective in patients undergoing dialysis","volume":"156","author":"Chuang","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2020.04.002_bib63","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2020.04.002_bib64","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ekir.2018.10.003","article-title":"Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir in patients with hepatitis C virus genotype 1 or 4 infection and advanced kidney disease","volume":"4","author":"Lawitz","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jfma.2020.04.002_bib65","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1111\/jgh.14672","article-title":"Paritaprevir\/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis","volume":"34","author":"Liu","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib66","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12072-019-09933-8","article-title":"Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?","volume":"13","author":"Hanafy","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2020.04.002_bib67","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/cld.808","article-title":"PRO: patients with decompensated cirrhosis listed for liver transplantation should be treated pretransplant","volume":"14","author":"Ukpong","year":"2019","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib68","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study","volume":"65","author":"Belli","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib69","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1111\/liv.13878","article-title":"Delisting HCV-infected liver transplant candidates who improved after viral eradication: outcome 2 years after delisting","volume":"38","author":"Perricone","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2020.04.002_bib70","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jhep.2017.08.008","article-title":"Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation","volume":"67","author":"Pascasio","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib71","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/cld.789","article-title":"CON: patients with decompensated cirrhosis listed for liver transplantation should be treated posttransplant","volume":"14","author":"Pedersen","year":"2019","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib72","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/hep.29097","article-title":"Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: analysis of data from the Hepa-C registry","volume":"65","author":"Fern\u00e1ndez Carrillo","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib73","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jhep.2015.05.029","article-title":"Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment","volume":"63","author":"Khatri","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib74","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1111\/hepr.12477","article-title":"Drug-induced liver injury in a chronic hepatitis C patient treated by peginterferon, ribavirin and simeprevir","volume":"45","author":"Okajima","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2020.04.002_bib75","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s40262-019-00774-0","article-title":"Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations: a 2019 update","volume":"58","author":"Smolders","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jfma.2020.04.002_bib76","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000007","article-title":"Elbasvir\/grazoprevir in people with hepatitis C genotype 1 infection and child-pugh class B cirrhosis: the C-SALT Study","volume":"10","author":"Jacobson","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jfma.2020.04.002_bib77","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib78","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib79","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence","volume":"63","author":"Poordad","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib80","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2020.04.002_bib81","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1016\/S0618-8278(19)30413-X","article-title":"THU-138-High efficacy and improvement in CPT class with sofosbuvir\/velpatasvir plus ribavirin for 12 weeks in patients with CPT C decompensated cirrhosis","volume":"70","author":"Flamm","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib82","doi-asserted-by":"crossref","first-page":"13699","DOI":"10.1038\/s41598-018-32060-7","article-title":"Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study","volume":"8","author":"Liu","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2020.04.002_bib83","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/JCMA.0000000000000148","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan","volume":"82","author":"Wu","year":"2019","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.jfma.2020.04.002_bib84","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jfma.2018.09.016","article-title":"Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan","volume":"118","author":"Cheng","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2020.04.002_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026703","article-title":"Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study","volume":"9","author":"Huang","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jfma.2020.04.002_bib86","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jgh3.12091","article-title":"Resolution of ascites and hepatic encephalopathy and absence of variceal bleeding in decompensated hepatitis C virus cirrhosis patients","volume":"2","author":"Romano","year":"2018","journal-title":"JGH Open"},{"key":"10.1016\/j.jfma.2020.04.002_bib87","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib88","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib89","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jhep.2019.04.017","article-title":"Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: a systematic review and meta-analysis","volume":"71","author":"Ji","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib90","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib91","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib92","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cgh.2019.07.042","article-title":"Provider attitudes and practice patterns for direct-acting antiviral therapy for patients with hepatocellular carcinoma","volume":"18","author":"Rich","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib93","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/apt.14823","article-title":"Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy","volume":"48","author":"Saraiya","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2020.04.002_bib94","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib95","first-page":"31","article-title":"No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis","volume":"5","author":"Rutledge","year":"2019","journal-title":"Hepatoma Res"},{"key":"10.1016\/j.jfma.2020.04.002_bib96","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1053\/j.gastro.2019.01.027","article-title":"Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study","volume":"156","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2020.04.002_bib97","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2019.07.040","article-title":"Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma","volume":"157","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2020.04.002_bib98","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","article-title":"Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients","volume":"71","author":"Cabibbo","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib99","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1245\/s10434-019-07911-w","article-title":"The achievement of a sustained virological response either before or after hepatectomy improves the prognosis of patients with primary hepatitis C virus-related hepatocellular carcinoma","volume":"26","author":"Okamura","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jfma.2020.04.002_bib100","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2018.09.029","article-title":"Impact of direct-acting antivirals on early recurrence of HCV-related HCC: comparison with interferon-based therapy","volume":"70","author":"Nishibatake Kinoshita","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib101","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/cam4.2061","article-title":"Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: a prospective multicenter cohort study","volume":"8","author":"Nakano","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib102","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.cgh.2018.10.038","article-title":"Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection","volume":"17","author":"Degasperi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib103","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jhep.2017.01.020","article-title":"Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals","volume":"66","author":"Prenner","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib104","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jhep.2017.02.027","article-title":"Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma","volume":"67","author":"Beste","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib105","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/hep4.1412","article-title":"Treatment status of hepatocellular carcinoma does not influence rates of sustained virologic response: an HCV-target analysis","volume":"3","author":"Radhakrishnan","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jfma.2020.04.002_bib106","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jfma.2019.09.006","article-title":"Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: fact or fiction?","volume":"119","author":"Hsu","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2020.04.002_bib107","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.13452","article-title":"Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response","volume":"37","author":"Bruno","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2020.04.002_bib108","article-title":"Cure with interferon free DAA is associated with increased survival in patients with HCV related HCC from both East and West","author":"Dang","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib109","article-title":"HCV cure rates are reduced in patients with active but not inactive hepatocellular carcinoma- A practice implication","author":"Ogawa","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib110","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/jhep.2002.31773","article-title":"Hepatitis C virus kinetics during and immediately after liver transplantation","volume":"35","author":"Garcia-Retortillo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib111","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/lt.25424","article-title":"Improved graft survival after liver transplantation for recipients with hepatitis C virus in the direct-acting antiviral era","volume":"25","author":"Cotter","year":"2019","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jfma.2020.04.002_bib112","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of glecaprevir\/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis","volume":"16","author":"Asselah","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib113","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.30046","article-title":"Glecaprevir\/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection","volume":"68","author":"Reau","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib114","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","article-title":"An interferon-free antiviral regimen for HCV after liver transplantation","volume":"371","author":"Kwo","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib115","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jfma.2017.06.006","article-title":"Paritaprevir\/ritonavir\/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: real-world experience","volume":"117","author":"Yu","year":"2018","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2020.04.002_bib116","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1056\/NEJMc1611829","article-title":"Perioperative ledipasvir-sofosbuvir for HCV in liver-transplant recipients","volume":"375","author":"Levitsky","year":"2016","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2020.04.002_bib117","first-page":"S22","article-title":"Pharmacokinetics and drug interactions of medications used to treat hepatitis C virus infection in the setting of chronic kidney disease and kidney transplantation","volume":"22","author":"Ortiz","year":"2018","journal-title":"Hemodial Int"},{"key":"10.1016\/j.jfma.2020.04.002_bib118","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M16-1205","article-title":"Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial","volume":"166","author":"Colombo","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib119","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2213-2600(19)30268-1","article-title":"Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial","volume":"8","author":"Cypel","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib120","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.29541","article-title":"Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: a partially randomized phase 3 clinical trial","volume":"67","author":"Wyles","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib121","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jfma.2017.02.017","article-title":"Taiwan's organ donation and transplantation: observation from national registry point of view","volume":"116","author":"Wang","year":"2017","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2020.04.002_bib122","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJM199108153250702","article-title":"Transmission of hepatitis C virus by organ transplantation","volume":"325","author":"Pereira","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib123","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa1812406","article-title":"Heart and lung transplants from HCV-infected donors to uninfected recipients","volume":"380","author":"Woolley","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib124","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1600-6143.2010.03091.x","article-title":"Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients","volume":"10","author":"Kucirka","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jfma.2020.04.002_bib125","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/ajt.13976","article-title":"Changes in utilization and discard of hepatitis C-infected donor livers in the recent era","volume":"17","author":"Bowring","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jfma.2020.04.002_bib126","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/j.jacc.2018.07.097","article-title":"Decline of increased risk donor offers on waitlist survival in heart transplantation","volume":"72","author":"Mulvihill","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2020.04.002_bib127","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMc1705221","article-title":"Trial of transplantation of HCV-infected kidneys into uninfected recipients","volume":"376","author":"Goldberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib128","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/M18-0749","article-title":"Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial","volume":"169","author":"Reese","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib129","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib130","doi-asserted-by":"crossref","first-page":"e13146","DOI":"10.1111\/tid.13146","article-title":"Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients","volume":"21","author":"Friebus-Kardash","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib131","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/ajt.15162","article-title":"Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors","volume":"19","author":"Kwong","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jfma.2020.04.002_bib132","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jamcollsurg.2018.12.004","article-title":"Use of hepatitis C virus antibody-positive donor livers in hepatitis C nonviremic liver transplant recipients","volume":"228","author":"Luckett","year":"2019","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jfma.2020.04.002_bib133","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1164\/rccm.201712-2614LE","article-title":"Lung transplantation from hepatitis C viremic donors to uninfected recipients","volume":"197","author":"Abdelbasit","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib134","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.healun.2018.01.1293","article-title":"Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies","volume":"37","author":"Schlendorf","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jfma.2020.04.002_bib135","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1111\/ajt.15311","article-title":"Transplanting hepatitis C virus-infected hearts into uninfected recipients: a single-arm trial","volume":"19","author":"McLean","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jfma.2020.04.002_bib136","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S2468-1253(19)30240-7","article-title":"Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study","volume":"4","author":"Bethea","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib137","first-page":"27A","article-title":"Transplantation from HCV-infected donors to HCV uninfected recipients: short course therapy to prevent transmission","volume":"70","author":"Feld","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib138","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/tid.12306","article-title":"Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant","volume":"16","author":"Hsiao","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib139","doi-asserted-by":"crossref","first-page":"296","DOI":"10.14218\/JCTH.2018.00016","article-title":"HBV-HCV coinfection: viral interactions, management, and viral reactivation","volume":"6","author":"Mavilia","year":"2018","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib140","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","article-title":"Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis","volume":"3","author":"M\u00fccke","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib141","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hep.29109","article-title":"Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis","volume":"66","author":"Chen","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2020.01.027","article-title":"Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV\/HCV co-infection","author":"Yeh","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib143","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1440-1746.2006.04547.x","article-title":"Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients","volume":"22","author":"Lee","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib144","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/apt.14352","article-title":"The negative impact of HBV\/HCV coinfection on cirrhosis and its consequences","volume":"46","author":"Pol","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2020.04.002_bib145","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s15010-004-3080-6","article-title":"Influence of chronic coinfection with hepatitis B and C virus on liver histology","volume":"32","author":"Sagnelli","year":"2004","journal-title":"Infection"},{"key":"10.1016\/j.jfma.2020.04.002_bib146","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1200\/JCO.2011.36.2335","article-title":"Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C","volume":"29","author":"Huang","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2020.04.002_bib147","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jfma.2018.11.008","article-title":"Taiwan consensus statement on the management of chronic hepatitis B","volume":"118","author":"Chien","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2020.04.002_bib148","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.2147\/IDR.S215974","article-title":"Management of patients with hepatitis B virus reactivation post-DAA treatment of chronic hepatitis C virus infection in HCV-HBV coinfected patients with pretreatment HBeAg seroconversion and early degree of hepatic fibrosis","volume":"12","author":"Osman","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jfma.2020.04.002_bib149","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/infdis\/jiy648","article-title":"Pretreatment hepatitis B viral load predicts long-term hepatitis B response after anti-hepatitis C therapy in hepatitis B\/C dual-infected patients","volume":"219","author":"Yeh","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib150","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13256-015-0630-8","article-title":"Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report","volume":"9","author":"Ende","year":"2015","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.jfma.2020.04.002_bib151","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s12328-016-0657-4","article-title":"A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?","volume":"9","author":"Hayashi","year":"2016","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.jfma.2020.04.002_bib152","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijid.2018.11.014","article-title":"Severe hepatitis B reactivation during direct-acting antiviral treatment in \"the absence\" of hepatitis B surface antigen","volume":"79","author":"Sastre","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib153","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/M13-1829","article-title":"Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study","volume":"160","author":"Lo Re","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib154","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jhep.2007.06.010","article-title":"Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study","volume":"47","author":"Br\u00e4u","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib155","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1086\/644771","article-title":"Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression","volume":"49","author":"Chen","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib156","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.23020","article-title":"Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus","volume":"50","author":"Berenguer","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib157","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/cid\/cis500","article-title":"Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus","volume":"55","author":"Berenguer","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib158","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Wyles","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib159","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","article-title":"Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Naggie","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib160","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/cid\/cix260","article-title":"Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase 3 study","volume":"65","author":"Wyles","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib161","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/cid\/ciy220","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study","volume":"67","author":"Rockstroh","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib162","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial","volume":"2","author":"Rockstroh","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jfma.2020.04.002_bib163","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2147\/IDR.S206938","article-title":"Grazoprevir\/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV\/HIV co-infection: a non-randomized, open-label clinical trial","volume":"12","author":"Lin","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jfma.2020.04.002_bib164","doi-asserted-by":"crossref","first-page":"ofx154","DOI":"10.1093\/ofid\/ofx154","article-title":"Safety and efficacy of ombitasvir, paritaprevir with ritonavir \u00b1 dasabuvir with or without ribavirin in patients with human immunodeficiency virus-1 and hepatitis C virus genotype 1 or genotype 4 coinfection: TURQUOISE-I Part 2","volume":"4","author":"Rockstroh","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib165","doi-asserted-by":"crossref","first-page":"ofz055","DOI":"10.1093\/ofid\/ofz055","article-title":"Direct-acting antiviral treatment failure among hepatitis C and HIV-coinfected patients in clinical care","volume":"6","author":"Rossi","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib166","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1177\/0956462419836520","article-title":"Hepatitis C treatment uptake and response among human immunodeficiency virus\/hepatitis C virus-coinfected patients in a large integrated healthcare system","volume":"30","author":"Lam","year":"2019","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.jfma.2020.04.002_bib167","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/cid\/cix111","article-title":"Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus\/hepatitis C virus genotype 1-coinfected patients treated in routine practice","volume":"64","author":"Bhattacharya","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib168","doi-asserted-by":"crossref","first-page":"ofx062","DOI":"10.1093\/ofid\/ofx062","article-title":"Highly successful hepatitis C virus (HCV) treatment outcomes in human immunodeficiency virus\/HCV-coinfected patients at a large, urban, ryan white clinic","volume":"4","author":"Patel","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib169","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jhep.2017.02.012","article-title":"Efficacy and safety of direct-acting antiviral regimens in HIV\/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort","volume":"67","author":"Piroth","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib170","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/cid\/ciw379","article-title":"All-oral direct-acting antiviral regimens in HIV\/hepatitis C virus-coinfected patients with cirrhosis are efficient and safe: real-life results from the prospective ANRS CO13-HEPAVIH Cohort","volume":"63","author":"Sogni","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib171","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.29814","article-title":"All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus\/HCV-coinfected subjects in real-world practice: madrid coinfection registry findings","volume":"68","author":"Berenguer","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib172","doi-asserted-by":"crossref","first-page":"ofz100","DOI":"10.1093\/ofid\/ofz100","article-title":"Effectiveness of direct-acting antiviral therapy in patients with human immunodeficiency virus-hepatitis C virus coinfection in routine clinical care: a multicenter study","volume":"6","author":"Kim","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib173","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/apt.15011","article-title":"Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan","volume":"48","author":"Liu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2020.04.002_bib174","doi-asserted-by":"crossref","first-page":"234","DOI":"10.14218\/JCTH.2016.00026","article-title":"HIV\/HCV antiviral drug interactions in the era of direct-acting antivirals","volume":"4","author":"Rice","year":"2016","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib175","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jinf.2011.04.005","article-title":"Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load","volume":"62","author":"Wang","year":"2011","journal-title":"J Infect"},{"key":"10.1016\/j.jfma.2020.04.002_bib176","doi-asserted-by":"crossref","first-page":"e1328","DOI":"10.1097\/MD.0000000000001328","article-title":"Hepatitis C virus infection is associated with an increased risk of active tuberculosis disease: a nationwide population-based study","volume":"94","author":"Wu","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.jfma.2020.04.002_bib177","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/aje\/kwu095","article-title":"Cirrhosis as a risk factor for tuberculosis infection--a nationwide longitudinal study in Taiwan","volume":"180","author":"Lin","year":"2014","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jfma.2020.04.002_bib178","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1186\/s12879-014-0705-y","article-title":"Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: a population-based cohort study in Taiwan","volume":"14","author":"Lin","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib179","doi-asserted-by":"crossref","first-page":"e01215","DOI":"10.1128\/AAC.01215-19","article-title":"A pharmacology perspective of simultaneous tuberculosis and hepatitis C treatment","volume":"63","author":"Kempker","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jfma.2020.04.002_bib180","series-title":"Ministry of health and welfare, R.O.C.(Taiwan). Taiwan guidelines for TB diagnosis & treatment (6E)","author":"Centers for Disease Control","year":"2017"},{"key":"10.1016\/j.jfma.2020.04.002_bib181","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcma.2017.10.002","article-title":"The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: a systematic review and meta-analysis","volume":"81","author":"Chang","year":"2018","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.jfma.2020.04.002_bib182","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1186\/s12879-019-4494-1","article-title":"Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis","volume":"19","author":"Musso","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib183","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","article-title":"HCV epidemiology in high-risk groups and the risk of reinfection","volume":"65","author":"Midgard","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib184","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jfma.2020.04.002_bib185","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1473-3099(17)30676-X","article-title":"Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study","volume":"18","author":"Zelenev","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib186","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/add.13948","article-title":"Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic","volume":"113","author":"Fraser","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.jfma.2020.04.002_bib187","article-title":"Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis","author":"Graf","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib188","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial","volume":"3","author":"Grebely","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib189","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/cid\/ciw580","article-title":"Efficacy and safety of ledipasvir\/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials","volume":"63","author":"Grebely","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib190","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/cid\/ciw579","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials","volume":"63","author":"Grebely","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib191","doi-asserted-by":"crossref","first-page":"ofy001","DOI":"10.1093\/ofid\/ofy001","article-title":"Sofosbuvir-based direct-acting antiviral therapies for HCV in people receiving opioid substitution therapy: an analysis of phase 3 studies","volume":"5","author":"Grebely","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib192","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib193","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugpo.2019.01.011","article-title":"Safety and efficacy of glecaprevir\/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy","volume":"66","author":"Grebely","year":"2019","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.jfma.2020.04.002_bib194","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.drugpo.2018.10.004","article-title":"Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy","volume":"62","author":"Grebely","year":"2018","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.jfma.2020.04.002_bib195","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S2468-1253(18)30304-2","article-title":"Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis","volume":"3","author":"Hajarizadeh","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib196","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jvh.13119","article-title":"Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: the C-SCOPE Study","volume":"26","author":"Litwin","year":"2019","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2020.04.002_bib197","doi-asserted-by":"crossref","first-page":"22146","DOI":"10.7448\/IAS.20.1.22146","article-title":"Elimination of HCV as a public health concern among people who inject drugs by 2030 - what will it take to get there?","volume":"20","author":"Grebely","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.jfma.2020.04.002_bib198","first-page":"35","article-title":"Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management","volume":"31","author":"Papadopoulos","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.jfma.2020.04.002_bib199","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012551","article-title":"The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment","volume":"97","author":"Qvigstad","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jfma.2020.04.002_bib200","doi-asserted-by":"crossref","first-page":"E335","DOI":"10.1002\/ajh.24427","article-title":"Long term survival in persons with hemophilia and chronic hepatitis C: 40 year outcomes of a large single center cohort","volume":"91","author":"Eyster","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jfma.2020.04.002_bib201","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/hae.12791","article-title":"Once daily ledipasvir\/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection","volume":"22","author":"Stedman","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jfma.2020.04.002_bib202","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/hae.13178","article-title":"Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders","volume":"23","author":"Walsh","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.jfma.2020.04.002_bib203","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186255","article-title":"Interferon-free therapy with direct acting antivirals for HCV\/HIV-1 co-infected Japanese patients with inherited bleeding disorders","volume":"12","author":"Uemura","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.jfma.2020.04.002_bib204","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/hep.29139","article-title":"Elbasvir\/grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a phase III study","volume":"66","author":"Hezode","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib205","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/hae.13829","article-title":"Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: a single-centre experience","volume":"25","author":"Fransen","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jfma.2020.04.002_bib206","doi-asserted-by":"crossref","first-page":"127","DOI":"10.5482\/HAMO-16-05-0014","article-title":"Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders","volume":"37","author":"Wiegand","year":"2017","journal-title":"H\u00e4mostaseologie"},{"key":"10.1016\/j.jfma.2020.04.002_bib207","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/QAI.0000000000001271","article-title":"Brief report: the impact of ledipasvir\/sofosbuvir on HIV-positive and HIV-negative Japanese hemophilia patients with 1, 4, and mixed-genotype HCV","volume":"74","author":"Nagao","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jfma.2020.04.002_bib208","doi-asserted-by":"crossref","first-page":"721","DOI":"10.5009\/gnl17209","article-title":"Direct acting antiviral agents in Korean patients with chronic hepatitis C and hemophilia who are treatment-na\u00efve or treatment-experienced","volume":"11","author":"Lee","year":"2017","journal-title":"Gut Liver"},{"key":"10.1016\/j.jfma.2020.04.002_bib209","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016524","article-title":"Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection","volume":"98","author":"Xiao","year":"2019","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jfma.2020.04.002_bib210","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jfma.2017.10.001","article-title":"The treatment outcome and impact on blood transfusion demand of Peg-interferon\/ribavirin in thalassemic patients with chronic hepatitis C","volume":"117","author":"Liang","year":"2018","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2020.04.002_bib211","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.dld.2016.02.004","article-title":"Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: is there still an indication?","volume":"48","author":"Di Marco","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib212","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/apt.14197","article-title":"Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection","volume":"46","author":"Mangia","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2020.04.002_bib213","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jmv.25314","article-title":"Acute changes in cardiac function by direct acting antiviral therapy for hepatitis C-infected patients with thalassemia","volume":"91","author":"Khosravi","year":"2019","journal-title":"J Med Virol"},{"key":"10.1016\/j.jfma.2020.04.002_bib214","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jceh.2017.06.002","article-title":"Safety and efficacy of sofosbuvir and daclatasvir for hepatitis C virus infection in patients with \u03b2-thalassemia major","volume":"8","author":"Mehta","year":"2018","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib215","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4103\/ijmm.IJMM_18_90","article-title":"The effectiveness of sofosbuvir and daclatasvir in the treatment of hepatitis C in thalassaemia major patients and their effect on haematological factors","volume":"36","author":"Zamani","year":"2018","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.jfma.2020.04.002_bib216","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25339","article-title":"Sofosbuvir\/velpatasvir for chronic hepatitis C infection in patients with transfusion-dependent thalassemia","volume":"94","author":"Sharara","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jfma.2020.04.002_bib217","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jceh.2017.08.002","article-title":"Generic direct acting antivirals in treatment of chronic hepatitis C infection in patients of thalassemia major","volume":"7","author":"Nagral","year":"2017","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib218","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/ajh.24911","article-title":"Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies","volume":"92","author":"Origa","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jfma.2020.04.002_bib219","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/bjh.14640","article-title":"Treatment of chronic hepatitis C with direct-acting antivirals in patients with \u03b2-thalassaemia major and advanced liver disease","volume":"178","author":"Sinakos","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jfma.2020.04.002_bib220","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.dld.2018.12.016","article-title":"Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent thalassemia major","volume":"51","author":"Ponti","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib221","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S2468-1253(19)30046-9","article-title":"Hepatitis C virus infection in children and adolescents","volume":"4","author":"Indolfi","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib222","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/hep.28995","article-title":"The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection","volume":"66","author":"Balistreri","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib223","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/hep.30123","article-title":"Safety and efficacy of ledipasvir-sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6-11","volume":"68","author":"Murray","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib224","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.30830","article-title":"Ledipasvir-sofosbuvir for 12 weeks in children 3 to <6 years old with chronic hepatitis C","volume":"71","author":"Schwarz","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib225","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/hep.29278","article-title":"Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection","volume":"66","author":"Wirth","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib226","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hep.30821","article-title":"Sofosbuvir and ribavirin therapy for children aged 3 to <12 years with hepatitis C virus genotype 2 or 3 infection","volume":"71","author":"Rosenthal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib227","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.30840","article-title":"Pharmacokinetics,safety, and efficacy of glecaprevir\/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study","volume":"71","author":"Jonas","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib228","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/cid\/ciu447","article-title":"Vertical transmission of hepatitis C virus: systematic review and meta-analysis","volume":"59","author":"Benova","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib229","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/hep.26519","article-title":"Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: a retrospective study","volume":"58","author":"Mohan","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib230","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/hep.22094","article-title":"Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial","volume":"47","author":"Goodman","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.04.002_bib231","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1053\/j.gastro.2009.06.040","article-title":"Coinfection with HIV-1 and HCV--a one-two punch","volume":"137","author":"Kim","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2020.04.002_bib232","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/jvh.13032","article-title":"Safety and efficacy of combined sofosbuvir\/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4","volume":"26","author":"Abdel Ghaffar","year":"2019","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2020.04.002_bib233","doi-asserted-by":"crossref","first-page":"833","DOI":"10.15585\/mmwr.mm6839a1","article-title":"National trends in hepatitis C infection by opioid use disorder status among pregnant women at delivery hospitalization - United States, 2000-2015","volume":"68","author":"Ko","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jfma.2020.04.002_bib234","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/apt.15476","article-title":"Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child","volume":"50","author":"Freriksen","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2020.04.002_bib235","doi-asserted-by":"crossref","first-page":"B2","DOI":"10.1016\/j.ajog.2017.07.039","article-title":"Hepatitis C in pregnancy: screening, treatment, and management","volume":"217","author":"Hughes","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jfma.2020.04.002_bib236","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/0003-4819-158-2-201301150-00575","article-title":"Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force","volume":"158","author":"Cottrell","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib237","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0140-6736(00)02681-7","article-title":"Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission","volume":"356","author":"Gibb","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2020.04.002_bib238","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1515\/jtim-2017-0001","article-title":"Ongoing transmission of HCV: should cesarean section be justified? data mining discovery","volume":"5","author":"Elrazek","year":"2017","journal-title":"J Transl Int Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib239","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/AOG.0000000000003062","article-title":"Short-term effects and long-term cost-effectiveness of universal hepatitis C testing in prenatal care","volume":"133","author":"Tasillo","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jfma.2020.04.002_bib240","series-title":"A phase 1 study of ledipasvir\/sofosbuvir in pregnant women with hepatitis C virus [abstract 87]","author":"Chappell","year":"2019"},{"key":"10.1016\/j.jfma.2020.04.002_bib241","first-page":"S292","article-title":"Treatment of chronic hepatitis C with ledipasvir\/sofosbuvir combination during pregnancy [Abstract]","volume":"12","author":"Yattoo","year":"2018","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2020.04.002_bib242","first-page":"e221","article-title":"THU-137-DAA therapy in women of child bearing age: accidental conception during therapy and pregnancy outcome","volume":"70","author":"El-Sayed","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib243","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-230529","article-title":"Successful sofosbuvir lead-in monotherapy for the treatment of hepatitis C virus (HCV) infection in a pregnant woman living with HIV","volume":"12","author":"Mandimika","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jfma.2020.04.002_bib244","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib245","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S0618-8278(19)30003-9","article-title":"GS-03-Global real world evidence of sofosbuvir\/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: integrated analysis of 12 clinical practice cohorts","volume":"70","author":"Mangia","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib246","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/apt.15222","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry","volume":"49","author":"Berg","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2020.04.002_bib247","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2020.04.002_bib248","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2020.04.002_bib249","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12072-019-09927-6","article-title":"Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India","volume":"13","author":"Sood","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2020.04.002_bib250","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jceh.2018.12.001","article-title":"Strategy and efficacy of generic and pan-genotypic sofosbuvir\/velpatasvir in chronic hepatitis C virus: a Myanmar experience","volume":"9","author":"Bwa","year":"2019","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jfma.2020.04.002_bib251","series-title":"Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis","year":"2016"},{"key":"10.1016\/j.jfma.2020.04.002_bib252","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/flgastro-2018-101114","article-title":"Overcoming barriers to hepatitis C elimination","volume":"10","author":"Mendizabal","year":"2019","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.jfma.2020.04.002_bib253","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S1473-3099(19)30170-7","article-title":"Taiwan commits to eliminating hepatitis C in 2025","volume":"19","author":"Chen","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jfma.2020.04.002_bib254","article-title":"A comprehensive people-centered outreach health-care system targeting HCV micro-elimination in hyperendemic areas of Taiwan (compact) \u2013 establishment of a model toward HCV elimination: interim report","volume":"70","author":"Yu","year":"2019","journal-title":"Hepatology"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664620301224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664620301224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:42:32Z","timestamp":1760539352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664620301224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":254,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0929664620301224"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2020.04.002","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2020.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}